A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy

Effect of serotonin modulation on dystrophin-deficient zebrafish

(2020) Janelle M. Spinazzola et al.   Biology Open

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

(2019) Yu Bai et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Epigenetic therapies in heart failure

(2019) Michael Alexanian et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

“The SINE compound KPT-350 blocks dystrophic pathologies in DMD zebrafish and mice”

(2019) Rylie M. Hightower et al.   MOLECULAR THERAPY

The effects of melatonin and curcumin on the expression of SIRT2, Bcl-2 and Bax in the hippocampus of adult rats

(2018) Arzu Keskin-Aktan et al.   BRAIN RESEARCH BULLETIN

The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment

(2018) Natasha C. Chang et al.   Cell Stem Cell

Current and Emerging Therapies for Duchenne Muscular Dystrophy

(2018) Megan Crone et al.   Current Treatment Options in Neurology

Tracking progress: an update on animal models for Duchenne muscular dystrophy

(2018) Dominic J. Wells   Disease Models & Mechanisms

Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy

(2018) Dongsheng Duan   MOLECULAR THERAPY

CRISPR Correction of Duchenne Muscular Dystrophy

(2018) Yi-Li Min et al.   Annual Review of Medicine

Progress toward Gene Therapy for Duchenne Muscular Dystrophy

(2017) Joel R. Chamberlain et al.   MOLECULAR THERAPY

BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells

(2017) Amy E. Campbell et al.   Skeletal Muscle

Epigenetic Therapeutics: A New Weapon in the War Against Cancer

(2016) Nita Ahuja et al.   Annual Review of Medicine

HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines

(2016) Y.-L. Wang et al.   CURRENT MOLECULAR MEDICINE

Histological effects of givinostat in boys with Duchenne muscular dystrophy

(2016) Paolo Bettica et al.   NEUROMUSCULAR DISORDERS

Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy

(2016) David G. Allen et al.   PHYSIOLOGICAL REVIEWS

Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model

(2016) In Young Choi et al.   Cell Reports

Epigenetic Reprogramming of Muscle Progenitors: Inspiration for Clinical Therapies

(2016) Silvia Consalvi et al.   Stem Cells International

Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy

(2016) Janelle M. Spinazzola et al.   Expert Opinion on Orphan Drugs

Using Touch-evoked Response and Locomotion Assays to Assess Muscle Performance and Function in Zebrafish

(2016) Tamar E. Sztal et al.   Jove-Journal of Visualized Experiments

Epigenetic therapy in gastrointestinal cancer: the right combination

(2016) Eihab Abdelfatah et al.   Therapeutic Advances in Gastroenterology

The Pathogenesis and Therapy of Muscular Dystrophies

(2015) Simon Guiraud et al.   Annual Review of Genomics and Human Genetics

Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy

(2015) J. W. McGreevy et al.   Disease Models & Mechanisms

Dasatinib as a treatment for Duchenne muscular dystrophy

(2015) Leanne Lipscomb et al.   HUMAN MOLECULAR GENETICS

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

(2015) Pawel K Mazur et al.   NATURE MEDICINE

Sirtuin-dependent epigenetic regulation in the maintenance of genome integrity

(2014) Laia Bosch-Presegué et al.   FEBS Journal

HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles

(2014) V. Saccone et al.   GENES & DEVELOPMENT

Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy

(2014) T. A. Waugh et al.   HUMAN MOLECULAR GENETICS

A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy

(2014) Jean K. Mah et al.   NEUROMUSCULAR DISORDERS

Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy

(2014) Silvia Consalvi et al.   Epigenomics

Muscle-Specific SIRT1 Gain-of-Function Increases Slow-Twitch Fibers and Ameliorates Pathophysiology in a Mouse Model of Duchenne Muscular Dystrophy

(2014) Angeliki Chalkiadaki et al.   PLoS Genetics

tRNA synthetase counteracts c-Myc to develop functional vasculature

(2014) Yi Shi et al.   eLife

Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment

(2013) Mei Li et al.   FASEB JOURNAL

Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling

(2013) Genri Kawahara et al.   HUMAN MOLECULAR GENETICS

Unknown

(2013) Silvia Consalvi et al.   MOLECULAR MEDICINE

Analysis of Skeletal Muscle Defects in Larval Zebrafish by Birefringence and Touch-evoke Escape Response Assays

(2013) Laura L. Smith et al.   Jove-Journal of Visualized Experiments

Quantification of birefringence readily measures the level of muscle damage in zebrafish

(2012) Joachim Berger et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy

(2012) Bradley S. Gordon et al.   CLINICAL NUTRITION

Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells

(2012) Dante Rotili et al.   JOURNAL OF MEDICINAL CHEMISTRY

NAD+ Biosynthesis Ameliorates a Zebrafish Model of Muscular Dystrophy

(2012) Michelle F. Goody et al.   PLOS BIOLOGY

Inhibitors of Histone Deacetylases

(2011) Kelly Huber et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish

(2011) Joachim Berger et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells

(2011) Guangbo Liu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Unknown

(2011) Silvia Consalvi et al.   MOLECULAR MEDICINE

Drug screening in a zebrafish model of Duchenne muscular dystrophy

(2011) G. Kawahara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy

(2010) Markus Riessland et al.   HUMAN MOLECULAR GENETICS

Dystrophin-deficient zebrafish feature aspects of the Duchenne muscular dystrophy pathology

(2010) Joachim Berger et al.   NEUROMUSCULAR DISORDERS

Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment

(2010) C. Colussi et al.   Proteomics Clinical Applications

Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy

(2009) Claudia Colussi et al.   FASEB JOURNAL

Characterization of Sirtuin Inhibitors in Nematodes Expressing a Muscular Dystrophy Protein Reveals Muscle Cell and Behavioral Protection by Specific Sirtinol Analogues

(2009) Matthieu Y. Pasco et al.   JOURNAL OF MEDICINAL CHEMISTRY

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

(2009) Katharine Bushby et al.   LANCET NEUROLOGY

Genetic isolation and characterization of a splicing mutant of zebrafish dystrophin

(2008) Jeffrey R. Guyon et al.   HUMAN MOLECULAR GENETICS

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect

(2008) E Lara et al.   ONCOGENE

HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment

(2008) C. Colussi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA